Amgen (STU:AMG) Short Interest


STU:AMG Amgen Inc STU:AMG
87 GF Score
Price €310.35
GF Value €310.99
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Amgen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:AMG vs GILD, PFE, BMY: Short Interest Comparison

For the Drug Manufacturers - General subindustry, Amgen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Short Interest distribution charts can be found below:

* The bar in red indicates where Amgen's Short Interest falls into.


STU:AMG
87GF Score
Amgen Inc STU:AMG
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amgen (STU:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €310.35 is trading 0.2% below its estimated GF Value™ of €310.99. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for STU:AMG:

  • Short Interest:
  • GF Value™: €310.99 vs. price of €310.35 (0.2% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the STU:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score

Get the complete analysis for STU:AMG

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€310.35
Price
€310.99
GF Value